In addition, Nakasone ES et al.[47] reported that infiltration of CCR2- expressing myeloid cells into chemotherapy-treated tumors contributes to tumor regrowth and relapse after treatment; recently, Sanford DE et al.[48] found that inflammatory monocyte (CD14+/CCR2+) recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease. The gene discussed is CCR2; the disease is neoplasm.